Currently Recruiting Clinical Trials
MULTIPLE MYELOMA BHV-1100
Biohaven is conducting a Phase 1a/1b study to establish safety and explore efficacy of infusing cytokine induced memory-like (CIML) NK cells plus BHV-1100, IVIG and low dose IL-2 into newly diagnosed multiple myeloma patients who have minimal residual disease (MRD+) in their first remission, prior to autologous stem cell transplant (ASCT).
All Biohaven Clinical Trials
Please use this button for information on past and current clinical trials being conducted by Biohaven. The button leads to the official clinicaltrials.gov website maintained by the U.S. government. For each study, the status column shows whether the study is active or no longer recruiting. Contact information is shown for each site under Locations.